stockrow
Friday 6 November 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
44.89
6.02
+15.49%
Follow EWTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
19.85 | 22.61 | 16.24 | 12.30 |
Net Debt/EBITDA |
9.32 | 9.16 | 7.41 | 36.12 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.87 | 0.74 | (0.07) | |
Capex/Depreciation |
0.08 | 0.61 | 0.15 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.38) | (0.40) | (0.39) | (0.72) | |
Cash per Share |
5.15 | 4.66 | 4.28 | 16.02 | |
Shareholders Equity per Share |
5.07 | 4.60 | 4.16 | 15.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.07 | 4.60 | 4.16 | 15.00 | |
Free Cash Flow |
(38.66) | (42.80) | (42.50) | (78.31) | |
Working Capital |
516.02 | 487.25 | 442.48 | 1,628.36 | |
Capital Expenditures |
(0.07) | (0.26) | (0.03) | (0.02) | |
Net Current Asset Value |
513.04 | 484.47 | 439.91 | 1,625.12 | |
| Other line items | |||||
Quick Ratio |
19.37 | 22.16 | 15.86 | 12.10 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.37) | (0.40) | (0.39) | (0.72) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.79 | 8.04 | 6.49 | 7.90 | |
Average Assets |
519.71 | 486.46 | 546.51 | 1,181.74 | |
Average Common Equity |
490.74 | 461.46 | 518.57 | 1,095.66 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026